Compare SUPN & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | BCC |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | 7680 |
| Industry | Biotechnology: Pharmaceutical Preparations | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2010 | 2012 |
| Metric | SUPN | BCC |
|---|---|---|
| Price | $47.64 | $86.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $61.60 | ★ $99.20 |
| AVG Volume (30 Days) | ★ 958.1K | 426.2K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.11 |
| Revenue | $392,755,000.00 | ★ $4,995,290,000.00 |
| Revenue This Year | $22.70 | $3.41 |
| Revenue Next Year | $19.14 | $4.76 |
| P/E Ratio | ★ N/A | $39.93 |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $40.32 | $65.00 |
| 52 Week High | $59.68 | $91.97 |
| Indicator | SUPN | BCC |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 61.25 |
| Support Level | $43.43 | $72.18 |
| Resistance Level | $47.55 | $87.52 |
| Average True Range (ATR) | 2.49 | 3.17 |
| MACD | -0.13 | 0.75 |
| Stochastic Oscillator | 41.87 | 71.81 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.